<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of Exclusive License: Development of Ocular Therapeutics Utilizing the Peptide C16Y and Related Peptides</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of Exclusive License: Development of Ocular Therapeutics Utilizing the Peptide C16Y and Related Peptides</h1>
    <p class="timestamp">Published: 2012-05-03 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to ODIN Biotech, a Texas corporation, having a place of business in Dallas, Texas, to practice the inventions embodied in the patents and patent applications belonging to the patent family having HHS Reference Number E-008-2004/0. The exclusive license is one which qualifie...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2012-10636</p>
    <p><strong>Publication Date:</strong> 2012-05-03</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2012/05/03/2012-10636/prospective-grant-of-exclusive-license-development-of-ocular-therapeutics-utilizing-the-peptide-c16y">https://www.federalregister.gov/documents/2012/05/03/2012-10636/prospective-grant-of-exclusive-license-development-of-ocular-therapeutics-utilizing-the-peptide-c16y</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2012-10636</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
